NUTX · Nutex Health Inc.
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jul 3, 2024; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $147.55M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA attributable to Nutex Health non-GAAP | $147.5M | Six Months Ended June 30, 2026 | — |
|
|
|||
| EBITDA non-GAAP | $162.45M | Six Months Ended June 30, 2026 | — |
| EBITDA attributable to Nutex Health non-GAAP | $162.5M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Hospital facilities | 27 | Three Months Ended June 30, 2026 | — |
| Total visits at the Hospital Division | 99,704 | Six Months Ended June 30, 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NUTX
this stock
Nutex Health Inc.
|
$1.29B | +14.0% | +82.4% | — | 16.1% |
|
HCA
HCA Healthcare, Inc.
|
$90.30B | -11.8% | +7.1% | 14.0 | 2.7% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$30.84B | -4.5% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.76B | +36.0% | +0.9% | 10.4 | 4.0% |
|
FMS
Fresenius Medical Care AG
|
$12.69B | -1.1% | +5.9% | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jul 3, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NUTX | +12.7% | +11.5% | +73.0% | +27.3% | +14.0% |
| SPY | -0.4% | +2.6% | +10.7% | +2.7% | +12.5% |
| vs SPY | +13.1% | +9.0% | +62.3% | +24.6% | +1.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.